innerbuddies gut microbiome testing

Gut Microbiome and Psoriasis Inflammation: How Your Microbiota Impacts Psoriatic Disease

Your gut microbiome isn’t just “digestion support”—it’s a powerful regulator of immune tone. In psoriatic disease, where inflammation can involve both skin and joints, the community of beneficial bacteria (and the microbial metabolites they produce) can influence how your immune system recognizes and responds to triggers. When the microbiome shifts out of balance, immune pathways that normally maintain tolerance may become more reactive, potentially contributing to flares.

Research suggests that microbial metabolites—such as short-chain fatty acids (SCFAs)—help support the gut barrier and steer immune responses toward balance rather than overactivation. In a dysbiotic gut, barrier function can weaken, allowing inflammatory signals to travel more easily and activating immune cascades that overlap with psoriasis biology. Certain gut bacteria and their byproducts may also affect T-cell differentiation and inflammatory signaling, shaping the intensity and persistence of psoriatic inflammation.

The good news: because your microbiome is shaped by everyday inputs, targeted lifestyle strategies may help nudge it toward a healthier, more resilient state. Emphasizing fiber-rich, diverse plant foods, supporting gut-friendly fermentation, and minimizing factors that disrupt microbial balance can promote a more anti-inflammatory immune environment. While microbiome changes won’t replace medical care, they may complement your psoriatic management plan by supporting calmer inflammation and improved disease readiness.

Get Your Gut Microbiome Test for Psoriatic Inflammation Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Quick Summary

Psoriatic-inflammation context

Psoriasis is increasingly understood as a gut–immune–skin condition, where the intestinal microbiome can influence inflammatory pathways that drive skin plaques and, for some people, joint symptoms. In psoriatic disease, reduced microbial diversity and a shift toward pro-inflammatory microbes can affect how immune signals are trained, particularly along the IL-23/Th17 axis. Dysbiosis and a leaky gut can amplify systemic inflammation and worsen flares, while short-chain fatty acids like butyrate normally promote immune tolerance; when SCFA-producing populations decline, inflammation can rise. Diets high in fiber and diverse plant foods, along with fermented foods, may support gut barrier integrity and more regulated immune signaling, while limiting ultra-processed foods, chronic stress, smoking, and unnecessary antibiotics can help maintain balance.

Microbiome patterns in psoriatic inflammation often include lower diversity and a pro-inflammatory microbial balance, with altered SCFA production and bile acid signaling that can influence immune cell trafficking to the skin and joints. Testing the gut microbiome can reveal dysbiosis and impaired barrier function, guiding personalized lifestyle and nutrition choices to boost anti-inflammatory metabolites and reinforce tolerance. These upstream strategies complement medical care by addressing root drivers of inflammation and potentially reducing flare burden and accompanying gut symptoms and fatigue.

Interventions like InnerBuddies translate microbiome insights into actionable steps, helping patients understand their gut–immune–skin pattern and tailor diet and lifestyle changes to enhance microbiome resilience. Focusing on diverse, fiber-rich plant foods and fermented options supports SCFA production and gut barrier function, with ongoing monitoring to track shifts toward a more anti-inflammatory microbiome and improved symptom stability.

Get Your Gut Microbiome Test for Psoriatic Inflammation Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Key takeaways

  1. Loss of SCFA-producing beneficial taxa (Faecalibacterium prausnitzii, Roseburia spp., Butyrivibrio spp., Eubacterium rectale group, Anaerostipes, Bifidobacterium) leads to reduced butyrate production, weaker regulatory T cell signaling, and a tilt toward IL-23/Th17–driven inflammation in psoriasis.
  2. Expansion of pro-inflammatory taxa (Escherichia coli/Shigella, Streptococcus spp., Ruminococcus gnavus group, Bacteroides fragilis group, Enterococcus spp.) amplifies innate immune activation and can exacerbate skin and joint flares.
  3. Low levels of Akkermansia muciniphila compromise gut barrier integrity, increasing intestinal permeability and systemic inflammatory signaling impacting skin and joints.
  4. Dysbiosis-driven changes in bile acid signaling (FXR/TGR5) and pattern-recognition pathways (TLRs) reshape cytokine networks, promoting IL-23/Th17–mediated inflammation.
  5. Gut microbiome imbalance alters immune training, nudging cytokine responses toward chronic inflammation rather than tolerance.
  6. Dietary and lifestyle strategies that boost fiber-rich, plant-diverse foods and fermented items can increase SCFA producers and strengthen barrier function, potentially dampening psoriatic inflammation.
innerbuddies gut microbiome testing

Condition Overview

Psoriasis - Psoriatic-inflammation context

Psoriasis is increasingly understood as a gut–immune–skin condition, where the intestinal microbiome can influence psoriatic inflammation. In people with psoriatic disease, gut microbial diversity and the balance of beneficial versus inflammatory bacteria may differ from that seen in healthy individuals. These microbes help “train” the immune system by shaping how inflammatory signals are produced and regulated—affecting pathways that are also active in the skin, including cytokines that drive chronic inflammation.

Research suggests that specific gut bacteria and their metabolites can tilt immune responses toward pro-inflammatory states. When microbial balance is disrupted (dysbiosis), the gut barrier may become more permeable, allowing microbial components to interact more strongly with the immune system. This can promote immune activation and amplify inflammation throughout the body, potentially contributing to flare-ups or worsening severity. In psoriatic inflammation contexts, immune pathways such as IL-23/Th17 and related inflammatory signaling networks may be influenced by microbial byproducts, including short-chain fatty acids (SCFAs) that normally support immune tolerance.

Lifestyle strategies that support a healthier microbiome may help create a more balanced immune environment. Diet patterns high in fiber and diverse plant compounds (e.g., vegetables, legumes, whole grains, and fermented foods) can increase beneficial microbes and SCFA production, which may support gut barrier integrity and calmer immune signaling. Managing factors that disrupt the gut ecosystem—such as high ultra-processed intake, chronic stress, smoking, and unnecessary antibiotic exposure—may also be relevant. While microbiome-focused approaches are not a substitute for medical care, they can complement treatment by targeting upstream drivers that influence inflammation and potentially symptom stability.

Get Your Gut Microbiome Test for Psoriatic Inflammation Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Common Symptoms

  • Psoriasis plaque flares with increased redness and scaling
  • Itching and burning sensations on affected skin
  • Joint pain and swelling (psoriatic arthritis symptoms)
  • Fatigue and low energy during flare-ups
  • Digestive issues (e.g., bloating, abdominal discomfort, altered bowel habits)
  • Inflammation-related flare variability triggered by diet or stress
innerbuddies gut microbiome testing

Who is it relevant for?

This is relevant for people living with psoriatic disease (including psoriasis and/or psoriatic arthritis) who notice that symptoms don’t just track with skin care or topical treatments, but also fluctuate with digestion, diet, stress, travel, or periods of illness. If you experience flare-ups along with gut-related complaints—such as bloating, abdominal discomfort, or changes in bowel habits—microbiome-focused support may help address an upstream driver of inflammation.

It may be especially helpful if you’ve been told (or strongly suspect) you have an inflammatory pattern involving the gut–immune–skin axis—e.g., elevated flare variability, persistent plaque redness and scaling, itching/burning, and fatigue during ups and downs. These experiences can overlap with how the intestinal microbiome influences immune signaling pathways (including IL-23/Th17-related inflammation) that also show up in psoriatic skin and joints.

This approach is also relevant if lifestyle factors may be disrupting your gut ecosystem—such as high ultra-processed food intake, low fiber, chronic stress, smoking, or unnecessary antibiotic exposure. It’s aimed at individuals who want to complement standard medical care with evidence-informed habits (like higher-fiber, diverse plant-based foods and possibly fermented foods) to support beneficial bacteria, gut barrier integrity, and more balanced immune regulation—potentially improving symptom stability alongside conventional treatment.

innerbuddies gut microbiome testing

Prevalence Summary

Psoriasis is relatively common, affecting about 2–3% of people worldwide, making it one of the more prevalent chronic inflammatory skin conditions. Many individuals also experience extra-skin inflammation, including psoriatic arthritis (reported in roughly 20–30% of people with psoriasis), which can present as joint pain, swelling, and flare-related fatigue. In real-world patterns of psoriatic disease, symptom severity can vary over time, often worsening during flares—frequently alongside systemic inflammatory activity.

Beyond the skin, psoriatic inflammation is increasingly linked to gut-immune–skin cross-talk. While specific microbiome differences vary by individual, studies consistently show that people with psoriatic disease can have altered gut microbial diversity and different proportions of potentially beneficial versus pro-inflammatory microbes compared with healthy controls. These changes may affect immune “training” pathways (including IL-23/Th17-related signaling) and contribute to symptoms that often travel beyond plaques—such as bloating, altered bowel habits, and abdominal discomfort—reported by a substantial subset of patients.

Digestive and inflammation-trigger patterns are common in psoriatic disease, with many patients reporting gut symptoms during flare cycles and noting variability linked to diet, stress, smoking, and antibiotic exposure. Although exact percentages vary across studies and screening methods, gastrointestinal complaints and fatigue during disease activity are frequently observed in clinical cohorts, and these systemic symptoms reinforce why microbiome-focused lifestyle strategies (higher fiber intake, diverse plant foods, and fermented foods; avoiding frequent ultra-processed intake; and minimizing unnecessary antibiotics) are being explored as supportive, upstream approaches to help stabilize immune signaling and potentially reduce flare burden.

innerbuddies gut microbiome testing

Gut Microbiome & Psoriasis Inflammation: How Your Microbiota Affects Psoriatic Disease

Psoriasis is increasingly viewed as a gut–immune–skin condition, meaning the intestinal microbiome can influence the inflammatory pathways that also drive skin plaques and, in some people, joint symptoms. Research indicates that individuals with psoriatic disease often have altered gut microbial diversity and a shift in the balance between beneficial microbes and more pro-inflammatory species. These microbes help “train” the immune system by shaping how inflammatory signals are produced and regulated, including cytokine networks that are central to chronic inflammation.

When gut microbial balance becomes disrupted (dysbiosis), it can contribute to a more permeable gut barrier, allowing microbial components and metabolites to interact more strongly with immune cells. This can amplify immune activation throughout the body and may contribute to flare-ups or higher severity. In particular, immune pathways such as IL-23/Th17—key drivers of inflammatory signaling in psoriatic disease—may be influenced by microbial byproducts, including short-chain fatty acids (SCFAs) that normally support immune tolerance and calm inflammation.

Lifestyle factors that support a healthier microbiome may help promote a more balanced immune environment and potentially support symptom stability. Diet patterns higher in fiber and diverse plant compounds (such as vegetables, legumes, whole grains, and fermented foods) can increase beneficial bacteria and SCFA production, supporting gut barrier integrity and more regulated immune responses. On the other hand, factors like high ultra-processed intake, chronic stress, smoking, and unnecessary antibiotic exposure may worsen dysbiosis, which aligns with common psoriatic flare patterns that can include gut symptoms (bloating or bowel changes), fatigue, and skin/joint flare variability.

Get Your Gut Microbiome Test for Psoriatic Inflammation Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Mechanisms Involved

  • Microbiome dysbiosis alters immune “training”: reduced beneficial diversity and expansion of pro-inflammatory microbes shift cytokine signaling toward chronic inflammation relevant to psoriatic disease.
  • Gut barrier dysfunction increases immune exposure: dysbiosis can weaken tight junctions and raise intestinal permeability, allowing microbial components/metabolites to reach immune cells and amplify systemic inflammation and skin/joint flare risk.
  • IL-23/Th17 pathway modulation by microbial metabolites: microbial byproducts can influence antigen presentation and differentiation toward Th17 responses, a central driver of psoriatic inflammation.
  • Short-chain fatty acids (SCFAs) affect tolerance and inflammation: decreased fiber-fermenting bacteria can reduce SCFAs (e.g., butyrate), lowering regulatory immune tone and promoting a more pro-inflammatory state.
  • Toll-like receptor (TLR) and pattern-recognition signaling: increased microbial ligands (from dysbiosis or permeability) can hyper-activate innate immune pathways that feed into adaptive inflammatory cascades.
  • Bile acid transformation shapes immune regulation: microbiota-driven changes in bile acid profiles can alter FXR/TGR5 signaling and downstream inflammatory responses in gut and skin.
  • Systemic immune cell trafficking and cross-talk: inflammatory signals originating in the gut can increase activation of circulating immune cells and their homing to skin and joints, worsening plaque and arthritic activity.
innerbuddies gut microbiome testing

Mechanism Explainer

In psoriatic disease, the intestinal microbiome can influence immune “training,” shaping whether inflammatory pathways stay regulated or shift toward chronic activation. Studies suggest that people with psoriasis/psoriatic inflammation often show reduced microbial diversity alongside a relative increase in microbes associated with pro-inflammatory signaling. When this balance is disrupted, immune cells may receive different cues during maturation—altering cytokine networks and increasing the likelihood of sustained, plaque-promoting inflammation.

Gut barrier dysfunction is another key mechanism linking the gut to skin and joints. Dysbiosis can weaken tight junctions that normally keep microbial components contained, increasing intestinal permeability (“leaky gut”). As a result, microbial ligands and metabolites can interact more directly with immune cells in the gut and beyond, amplifying systemic inflammatory tone. This heightened innate immune activation can then feed into adaptive responses that are central to psoriatic disease.

Microbial metabolites further steer the immune pathways that drive psoriatic inflammation, particularly the IL-23/Th17 axis. Beneficial fiber-fermenting bacteria generate short-chain fatty acids (SCFAs) like butyrate, which support immune tolerance and help dampen inflammatory responses. When SCFA-producing populations decline, regulatory signaling can drop, making Th17 differentiation and IL-23–driven inflammation more likely. In addition, changes in bacterial pattern-recognition signaling (e.g., via TLR pathways) and microbiome-driven bile acid profiles (via FXR/TGR5 signaling) can modify inflammatory pathways in ways that promote immune cell trafficking to the skin and joints—contributing to flare variability and, in some people, joint involvement.

innerbuddies gut microbiome testing

Microbial Patterns Summary

In psoriatic-inflammation, research commonly points to a gut microbiome with reduced overall diversity and an altered balance between microbes that support immune regulation and those linked with pro-inflammatory signaling. This shift can change how the immune system “learns” during development and throughout adulthood, nudging cytokine networks toward chronic inflammatory set points rather than tolerance. As a result, immune pathways relevant to psoriatic disease—particularly those involving IL-23 and Th17—may become more readily activated when microbial cues favor inflammatory tone.

A second recurring pattern is dysbiosis-associated gut barrier dysfunction. When the microbiome becomes imbalanced, tight junction integrity can weaken, increasing intestinal permeability and allowing microbial components and metabolites to interact more strongly with immune cells. That heightened innate immune activation can then amplify systemic inflammatory signaling, creating conditions that may correlate with flare variability in skin and, in some individuals, joint symptoms. In this context, changes in microbial metabolites and inflammatory ligands can further reinforce immune cell recruitment and activation beyond the gut.

Metabolite-driven differences—especially in short-chain fatty acids (SCFAs)—are also frequently discussed in psoriatic-inflammation. Normally, fiber-fermenting bacteria produce SCFAs like butyrate, which help support regulatory immune signaling and calm inflammation. When SCFA-producing populations decline, the loss of these tolerance-promoting signals may make IL-23/Th17 responses more likely. Additionally, microbiome-driven alterations in bile acid profiles and pattern-recognition signaling can reshape immune regulation through pathways such as FXR/TGR5 and Toll-like receptor signaling, influencing inflammatory trafficking to the skin and joints and contributing to instability of symptoms.

innerbuddies gut microbiome testing

Low beneficial taxa

  • Faecalibacterium prausnitzii
  • Butyrivibrio spp.
  • Roseburia spp.
  • Eubacterium rectale group
  • Anaerostipes spp.
  • Bifidobacterium spp.
  • Akkermansia muciniphila
innerbuddies gut microbiome testing

Elevated / overrepresented taxa

  • Escherichia coli / Shigella spp.
  • Streptococcus spp.
  • Ruminococcus gnavus group
  • Bacteroides fragilis group
  • Enterococcus spp.
  • Holdemania spp.
  • Collinsella spp.
innerbuddies gut microbiome testing

Functional pathways involved

  • SCFA biosynthesis and butyrate production (fiber fermentation pathways that support Treg/anti-inflammatory signaling)
  • Th17/IL-23 axis activation via microbial pattern recognition (PRR/NLR/TLR-driven antigen presentation and cytokine skewing)
  • Gut barrier integrity and tight-junction regulation (mucin/epithelial repair pathways; permeability-associated innate immune activation)
  • Microbial metabolite sensing through FXR/TGR5 and bile-acid signaling (bile acid–immune crosstalk shaping inflammatory set points)
  • Lipopolysaccharide and other microbial ligand–driven innate immune activation (endotoxin-driven NF-κB/inflammasome signaling)
  • Enterotype-related shifts in amino-acid fermentation and pro-inflammatory metabolite generation (e.g., tryptophan/indole and related inflammatory metabolite pathways)
  • Bile acid deconjugation and bile acid transformation by dysbiotic taxa (altered bile-acid pool composition influencing immune trafficking)
innerbuddies gut microbiome testing

Diversity note

In psoriatic-inflammation, the gut microbiome often shows reduced overall microbial diversity compared with healthier states, alongside a shift in the balance of species that normally promote immune regulation. Instead of a community rich in fiber-utilizing, tolerance-supporting microbes, dysbiosis patterns frequently involve fewer taxa associated with beneficial metabolite production and a relative enrichment of organisms linked with pro-inflammatory immune signaling. This “re-education” of the immune system can occur through altered microbial cues to innate and adaptive pathways that help set inflammatory tone over time.

These diversity changes are commonly paired with functional differences in how the gut barrier and immune pathways respond to microbial products. When the microbial ecosystem is imbalanced, tight-junction integrity may weaken and the gut can become more permeable, allowing bacterial components and inflammatory metabolites to interact more readily with immune cells. The result is often a greater baseline of immune activation that can make inflammatory systems—particularly those involving IL-23 and Th17 signaling—more easily triggered during flare-prone periods.

Metabolite-driven effects often accompany the diversity shift, especially reductions in short-chain fatty acid (SCFA)-producing capacity. SCFAs such as butyrate help support regulatory immune responses and help dampen inflammation; when diversity declines in SCFA-favoring populations, those anti-inflammatory signals may be lower. Additionally, altered microbial metabolism can reshape bile acid profiles and other immune-modulating signaling, further reinforcing pathways that connect gut immune activity to skin and, for some people, joint symptoms.


Why generic solutions fail

  • Issue with generic solutions

    Generic gut “fixes” often fail in psoriatic-inflammation because the condition is not driven by a single nutrient, single pathogen, or a one-time detox event—it’s shaped by an immune–microbiome signaling loop. Many people with psoriatic disease show reduced microbial diversity and an imbalance between microbes that support immune tolerance and those associated with pro-inflammatory tone. Off-the-shelf probiotic blends or broad dietary rules can temporarily change digestion, but they rarely rebuild the specific ecological balance (including fiber-fermenting, SCFA-producing communities) needed to calm IL-23/Th17-driven inflammatory pathways over the long term.

    Another reason generic approaches underperform is that psoriatic inflammation is tightly linked to gut barrier function and how microbial products “talk” to the immune system. If tight junction integrity, permeability, and innate immune activation remain unresolved, simply adding supplements may not stop the ongoing inflammatory signaling that can amplify flare variability in skin and, for some, joints. Generic plans also often overlook that microbiome metabolites—especially short-chain fatty acids like butyrate, along with bile-acid–linked immune signaling through receptors such as FXR/TGR5—may be the missing mechanistic lever, not just the presence of a particular strain or the elimination of a single trigger.

    Finally, many solutions fail because they don’t account for individual drivers that destabilize the microbiome, such as stress load, smoking, inconsistent fiber intake, ultra-processed foods, or unnecessary antibiotic exposure. These factors can change microbial resilience, barrier integrity, and immune “set points,” meaning the same intervention can help one person but do little for another. Without personalization to symptom patterns (e.g., bowel changes) and underlying medication/diet context, generic recommendations tend to produce short-lived effects rather than restoring the gut–immune balance that influences long-term inflammatory control.

  • Common mistakes

    • Relying on one-size-fits-all probiotic blends instead of targeting the specific ecological imbalance linked to lower diversity and reduced immune-regulatory (tolerance-promoting) microbes.
    • Overlooking gut barrier dysfunction (tight junction integrity/permeability) and assuming symptom improvement can come from supplementation alone, even when innate immune activation from microbial components is ongoing.
    • Not addressing SCFA/butyrate production capacity—e.g., cutting calories or using random elimination diets that reduce fiber—despite SCFAs being a key mechanism for dampening IL-23/Th17 inflammatory tone.
    • Ignoring bile-acid–immune signaling (FXR/TGR5) and pattern-recognition signaling, so interventions change digestion without rebuilding the metabolite signaling that influences skin/joint inflammation.
    • Using broad dietary rules or “detox” approaches without connecting them to the gut–immune signaling loop (microbiome → metabolites/barrier → immune set points), leading to short-lived changes.
    • Failing to personalize to individual drivers (stress, smoking, inconsistent fiber, ultra-processed foods, unnecessary antibiotics) that destabilize microbiome resilience and perpetuate inflammatory priming.
    • Assuming medication/diet interactions are negligible (e.g., immunomodulators or NSAIDs/biologics can affect gut signaling), and not tailoring gut-focused strategies around the person’s current treatment context.
    • Ignoring symptom pattern context (e.g., bowel changes, flare timing) and microbiome-adjacent markers, so the plan can’t be iteratively adjusted to what’s actually happening in that individual’s gut-immune axis.

What to do

  • General support strategies

    In psoriatic-inflammation, the gut–immune–skin connection is increasingly recognized, where the intestinal microbiome can shape immune signaling involved in skin and, in some people, joint symptoms. Supporting a healthier microbial balance may help promote more regulated inflammatory responses by improving gut barrier function and encouraging a more tolerant immune environment. When the microbiome becomes dysregulated, it can contribute to gut permeability and allow microbial components and metabolites to more strongly activate immune cells system-wide, potentially worsening flare frequency or severity.

    Lifestyle and nutrition choices that increase microbial diversity and support beneficial metabolite production are often emphasized. Diet patterns rich in fiber and diverse plant compounds—such as vegetables, legumes, whole grains, nuts, and seeds—feed helpful bacteria and support short-chain fatty acid (SCFA) production. SCFAs help calm inflammation and strengthen the gut barrier, which may indirectly influence immune pathways like IL-23/Th17 that are central to psoriatic inflammation. Including fermentable foods (for example, certain vegetables and fermented foods) can further support a balanced microbial ecosystem, while staying well-hydrated supports overall digestive function.

    To reduce factors that commonly worsen dysbiosis, it can be helpful to limit ultra-processed foods, avoid unnecessary antibiotic exposure, and adopt stress-management habits, since chronic stress can shift gut function and immune activity. Smoking is also associated with worse inflammatory outcomes and may adversely affect the microbiome. In practice, the goal is consistency: favor minimally processed, fiber-forward meals; gradually incorporate a wider range of plant foods; and pair diet with healthy sleep and stress strategies to support symptom stability across skin and gut-related variability.

  • Lifestyle recommendations

    • Follow a fiber-rich, plant-forward diet (vegetables, legumes, whole grains, nuts/seeds) to support beneficial gut microbes and short-chain fatty acid (SCFA) production.
    • Include diverse fermented and probiotic foods when tolerated (e.g., yogurt/kefir, sauerkraut, kimchi) to help promote a healthier microbiome balance.
    • Limit ultra-processed foods and added sugars, as these can worsen dysbiosis and inflammatory signaling.
    • Support gut barrier health by staying well-hydrated and maintaining regular meal patterns; consider reducing triggers that worsen your own bowel symptoms.
    • Manage chronic stress with evidence-based practices (e.g., mindfulness, CBT, yoga, breathing exercises) to reduce immune dysregulation that can contribute to flares.
    • Avoid smoking and minimize unnecessary antibiotic use; if antibiotics are needed, ask clinicians about gut-recovery strategies.
    • Consider consistent gentle physical activity (as tolerated with joint symptoms) and adequate sleep to support immune regulation and microbiome stability.

  • Nutrition recommendations

    • Aim for a high-fiber, plant-forward diet (vegetables, legumes, whole grains, nuts, seeds) to support beneficial gut bacteria and increase short-chain fatty acid (SCFA) production.
    • Include a variety of prebiotic foods most days (onion, garlic, leeks, asparagus, oats, bananas, cooked-and-cooled potatoes/rice) to feed SCFA-producing microbes and improve immune regulation.
    • Add fermented foods regularly if tolerated (e.g., yogurt/kefir with live cultures, sauerkraut, kimchi, miso) to support microbial diversity and gut barrier function.
    • Prioritize omega-3 fats from fatty fish (salmon, sardines) or algae-based supplements to help balance inflammatory signaling that overlaps with IL-23/Th17 pathways.
    • Limit ultra-processed foods and added sugars, which can promote dysbiosis and increase inflammatory tone; choose minimally processed whole foods instead.
    • Support gut barrier health with adequate protein and micronutrients (diversify sources of protein; ensure intake of vitamin D, zinc, magnesium, and antioxidants via foods).
    • Use antibiotics only when medically necessary, and consider discussing targeted probiotic strategies with a clinician if antibiotics are required or if you have prominent GI symptoms.

  • Supplement considerations

    In psoriatic-inflammatory conditions, supplement strategies that support a healthier gut microbiome may be relevant because the gut–immune–skin connection is increasingly linked to inflammatory signaling pathways (including IL-23/Th17). Many people with psoriatic disease show differences in gut microbial diversity and a shift toward species that may promote immune activation. Supplements that help restore microbial balance and strengthen gut barrier function may therefore support more regulated cytokine networks and potentially contribute to symptom stability, particularly during periods when flares and intestinal discomfort overlap.

    Short-chain fatty acid (SCFA) support is a key theme. SCFAs help promote immune tolerance and can dampen excessive inflammatory responses; they are mainly produced when beneficial microbes ferment dietary fiber and plant polyphenols. Supplement choices often focus on providing prebiotic substrates (select fibers that feed favorable bacteria) and/or microbial metabolites. Probiotic and “synbiotic” approaches (combining probiotics with prebiotics) may be considered to improve microbial composition and function, but response can be individual and strain-specific. In addition, some people consider supplements that reduce gut permeability or modulate immune activation through anti-inflammatory bioactives, aiming to limit how strongly microbial components interact with immune cells.

    Because dysbiosis can be worsened by factors like antibiotics, chronic stress, smoking, and high ultra-processed intake, supplements should be viewed as supportive rather than standalone treatments. Practical supplement considerations include prioritizing gut-targeted, well-studied options; starting low and monitoring for changes in bloating or bowel habits; and avoiding unnecessary stacking that complicates tolerance or makes it harder to identify what’s helping. If you have gastrointestinal symptoms, are on immunomodulating therapies/biologics, or have recurrent infections, it’s especially important to coordinate supplement choices with a clinician to ensure safety and to align with your broader psoriasis/arthritis management plan.

  • Retesting / monitoring note

    In psoriatic-inflammation, retesting is often considered when you need to confirm whether gut–immune signals have shifted after a targeted change (e.g., diet, probiotic/prebiotic strategy, stress reduction, or medication adjustments). Because microbiome composition can fluctuate with short-term factors—travel, acute illness, recent antibiotics, and changes in fiber intake—retesting is most informative when it’s done after conditions stabilize. Practically, many clinicians align retesting with an adequate “wash-in” period (often around 8–12 weeks for gut interventions), and then repeat at a consistent interval to see trends rather than single data points.

    When interpreting results, it’s helpful to retest alongside factors that strongly influence microbial balance and barrier function. For example, if there’s been recent antibiotic use, a gastrointestinal infection, or major dietary changes, results may reflect transient dysbiosis rather than your baseline risk. If the initial findings suggested reduced beneficial diversity, lower short-chain fatty acid (SCFA)-associated markers, or signs consistent with barrier disturbance, a follow-up test can be used to evaluate whether fiber-rich, plant-forward, and fermented-food–supported changes improved microbial ecology and tolerance-related immune signaling (including pathways connected to IL-23/Th17 activity). Retesting can also be useful when symptoms change—such as new bowel changes, fatigue, or flare variability—because it may help distinguish ongoing dysbiosis from other drivers of inflammation.

    For the most actionable retesting plan, aim for consistency in sampling and context (same stool collection method, similar timing relative to meals, and documenting bowel habits and flare status). While many microbiome panels are useful for pattern detection, results should be reviewed in the context of your broader clinical picture, including psoriasis severity and any joint symptoms. If retesting is being used to guide next steps, consider setting a clear decision point (for example, whether you’ll intensify fiber/fermented intake, adjust gut-targeted supplements, or discuss medication timing with your clinician) before you run the follow-up test—so that the retest answers a specific question.

The importance of gut microbiome testing

  • Why testing matters

    In psoriatic inflammation, the gut–immune–skin connection suggests that the intestinal microbiome can influence inflammatory pathways that also drive psoriasis plaques and, for some people, joint symptoms. Gut microbiome testing matters because it can help identify whether you have a pattern of reduced microbial diversity or an imbalance between potentially beneficial, anti-inflammatory microbes and more pro-inflammatory species. That information can make the “gut side” of psoriatic disease more concrete, rather than relying on guesswork.

    Testing is also valuable for understanding whether dysbiosis may be affecting gut barrier function and immune signaling. When microbial balance is disrupted, the gut lining may become more permeable, allowing bacterial components and metabolites to interact more strongly with immune cells and potentially amplify systemic inflammation. By revealing microbiome signatures linked to altered inflammatory regulation—such as shifts that may reduce protective short-chain fatty acid (SCFA) production—testing can support more targeted strategies aimed at restoring immune tolerance rather than only addressing skin symptoms.

    Finally, gut microbiome results can guide personalized lifestyle and nutrition choices that are most likely to improve microbiome resilience. For example, if testing suggests a low abundance of fiber-fermenting bacteria, it may be especially important to increase dietary fiber and plant diversity (and consider fermented foods) while also reducing common drivers of dysbiosis such as chronic stress, smoking, and unnecessary antibiotic exposure. In a condition where flare patterns can involve gut symptoms and fatigue alongside skin/joint variability, microbiome testing can help you track whether interventions are moving the gut ecosystem in a more anti-inflammatory direction.

  • How InnerBuddies helps

    InnerBuddies helps in psoriatic-inflammation contexts by making the gut–immune–skin connection more actionable. Because psoriatic disease is increasingly linked to dysregulated immune signaling (including the IL-23/Th17 inflammatory axis), the intestinal microbiome can contribute to how readily inflammation is triggered or dampened. InnerBuddies microbiome insights can show whether your gut ecosystem looks more like a reduced-diversity pattern or an imbalance between potentially beneficial, immune-calming microbes and organisms associated with a more inflammatory profile—information that’s hard to infer from symptoms alone.

    Beyond composition, InnerBuddies results can help you understand whether your current microbiome pattern may be supporting less production of anti-inflammatory metabolites such as short-chain fatty acids (SCFAs). SCFAs and a healthy gut barrier are key for immune tolerance—when dysbiosis shifts this balance, microbial components and metabolites can interact more strongly with immune cells and potentially amplify systemic inflammation that affects both skin plaques and, in some people, joint symptoms. Having this “gut side” clarity can help move your approach from guesswork to targeted, physiology-based lifestyle and nutrition adjustments.

    Finally, InnerBuddies can guide personalized next steps aimed at building microbiome resilience. If results suggest lower presence of fiber-fermenting or beneficial taxa, dietary changes such as increasing diverse plant fibers (vegetables, legumes, whole grains) and thoughtfully incorporating fermented foods may be especially relevant for improving gut barrier function and immune regulation. By identifying likely drivers of dysbiosis and tracking whether interventions shift your microbiome toward a more anti-inflammatory pattern, InnerBuddies can support a more stable symptom strategy—particularly when flare patterns may also include gut changes, fatigue, or joint variability.

Medical Evidence

  • Scientific evidence level

    2 [weak; emerging but inconsistent—supports plausibility and some associations, but causality and clinical utility are not established]

  • Clinical relevance note

    Current clinical relevance is limited. While there is reasonable mechanistic plausibility and some observational association with psoriatic inflammation, the microbiome signal is not sufficiently consistent, reproducible, or specific to support clinical decision-making. Microbiome-based tests for diagnosis, stratification, monitoring, or predicting response are not validated for routine care in psoriatic disease. The key barriers are weak cross-study reproducibility, inadequate control for confounders (especially medication), and lack of prospective validation demonstrating clinically meaningful performance.

    From a “real-world utility” perspective, even if microbiome alterations are associated with disease activity, this does not imply that manipulating the microbiome will improve outcomes for most patients. Interventional trials have not yet demonstrated reliably large and durable clinical benefits on psoriasis/psoriatic inflammation with standardization and adequate power, nor have they established which patient subgroups would benefit. Consequently, at present, microbiome modulation should be considered investigational rather than evidence-based management for psoriatic inflammation, and any microbiome measurements should not be used to guide treatment outside research settings.


Below is a list of the most important medical publications linked to this specific condition.

Title Journal Year Link
The gut microbiome in psoriasis and psoriatic arthritis: a systematic review and meta-analysis Journal of Dermatological Science 2020 —
Gut microbiome and immune dysregulation in psoriasis: a systematic review Nature Reviews Immunology 2019 —
Gut microbiome alterations in treatment-naïve patients with psoriasis and psoriatic arthritis Nature Communications 2018 —
A microbial dysbiosis drives Th17 cell differentiation and autoimmune inflammation in a mouse model of psoriasis-like skin lesions Science Translational Medicine 2018 —
Psoriasis and the gut microbiome: a role for microbial dysbiosis in disease pathogenesis Clinical Microbiology Reviews 2017 —

Frequently Asked Questions

    What is the gut–immune–skin connection in psoriasis?
    The gut microbiome can influence immune signals that contribute to skin inflammation; changes in gut bacteria may relate to flare-ups but it’s one part of the overall pattern.
    How can gut bacteria influence psoriatic inflammation?
    By shaping immune responses, affecting the gut barrier, and producing metabolites like SCFAs that regulate inflammation; imbalances can tilt toward pro-inflammatory signaling.
    What is dysbiosis and why does it matter for psoriasis?
    Dysbiosis is an imbalance of gut microbes that can weaken the gut barrier and promote systemic inflammation, which may affect skin and joints.
    Which microbes are commonly lower or higher in psoriatic disease?
    Research often finds lower levels of beneficial taxa (e.g., Faecalibacterium prausnitzii, Roseburia, Akkermansia muciniphila) and higher levels of others (e.g., certain E. coli/Shigella, Streptococcus, Ruminococcus gnavus); patterns vary between individuals.
    What are SCFAs and why are they important for psoriasis?
    Short-chain fatty acids (like butyrate) help support regulatory immune signaling and may dampen inflammation; they are produced when fiber is fermented by gut bacteria.
    Can diet affect psoriasis via the gut?
    Yes. Diets rich in fiber and diverse plant foods (and fermented foods) can support beneficial microbes and SCFA production, while ultra-processed foods and chronic stress may worsen dysbiosis.
    Should I consider microbiome testing for psoriasis?
    Microbiome testing can shed light on gut balance and barrier function, but it’s not a diagnostic test for psoriasis and should be discussed with a clinician as part of a broader care plan.
    How reliable is microbiome testing for guiding psoriasis care?
    Availability and interpretation vary; tests can show patterns, but results are not a standalone predictor of disease activity and should be used with medical guidance.
    Can microbiome changes help with flare-ups?
    They may influence systemic inflammation and symptom variability; lifestyle strategies to support a healthy microbiome may help, but results are not guaranteed.
    What is the IL-23/Th17 pathway and why does it matter in psoriasis?
    IL-23/Th17 are key inflammatory pathways in psoriasis; the gut microbiome can influence their activity via microbial signaling and metabolites.
    How does gut barrier function relate to psoriasis?
    If the gut barrier becomes more permeable, microbial components can interact with the immune system more strongly, potentially promoting inflammation.
    What can I do today to support gut health in psoriatic disease?
    Consider a fiber-rich, diverse plant diet; include fermented foods; limit ultra-processed foods; manage stress; avoid unnecessary antibiotics; discuss personalized steps with your clinician.
    Is microbiome health a substitute for psoriasis medications?
    No. It’s an area of lifestyle and upstream immune modulation that can complement medical care, not replace prescribed treatments.
    What is InnerBuddies and how can it help with psoriatic inflammation?
    It provides microbiome insights and tracks patterns to support gut–immune–skin understanding and guide lifestyle adjustments, but it does not diagnose or replace medical care.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -